Effects of esomeprazole on the pharmacokinetics of atazanavir and fosamprenavir in a patient with human immunodeficiency virus infection

Pharmacotherapy

Volumn 26, Issue 4, 2006, Pages 511-514

  Kiser, Jennifer J ^a   Lichtenstein, Kenneth A ^a   Anderson, Peter L ^a   Fletcher, Courtney V ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Atazanavir; Esomeprazole; Fosamprenavir; HIV; Human immunodeficiency virus; Omeprazole; Pharmacokinetics; Proton pump inhibitor

Indexed keywords

ALPHA TOCOPHEROL; AMINO ACID; AMPRENAVIR PHOSPHATE; ASCORBIC ACID; ASTRAGALUS EXTRACT; ATAZANAVIR; CHONDROITIN; CYANOCOBALAMIN; ESOMEPRAZOLE; FISH OIL; FOLIC ACID; GINGER EXTRACT; GINKGO BILOBA EXTRACT; GLUCOSAMINE; PROTON PUMP INHIBITOR; RITONAVIR; SELENIUM; SILYBUM MARIANUM EXTRACT; STAVUDINE; TAMSULOSIN; TENOFOVIR; UBIDECARENONE; XANTHOPHYLL; ZINC;

AGED; AREA UNDER THE CURVE; ARTICLE; CASE REPORT; CLINICAL FEATURE; DRUG BLOOD LEVEL; GASTROESOPHAGEAL REFLUX; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATIENT COMPLIANCE; PROSTATE HYPERTROPHY; SYMPTOM;

AGED; ANTI-HIV AGENTS; ANTI-ULCER AGENTS; CARBAMATES; DRUG INTERACTIONS; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; OLIGOPEPTIDES; OMEPRAZOLE; PHOSPHORIC ACID ESTERS; PROSPECTIVE STUDIES; PROTON PUMPS; PYRIDINES; SULFONAMIDES;

EID: 33645671146     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.4.511     Document Type: Article

References (6)

1. Bristol-Myers Squibb Company. Reyataz (atazanavir sulfate) package insert. Princeton, NJ; 2005.
2. Agarwala S, Gray K, Wang Y, Grasela D. Pharmacokinetic (PK) effect of omeprazole (OMP) on atazanavir (ATV) with ritonavir (RTV) in healthy subjects. Poster presentation at the 12th conference on retroviruses and opportunistic infections, Boston, MA, February 22-25, 2005.
3. Wire MB, Ballow C, Preston SL, et al. Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers. AIDS 2004;18:897-907.
4. Bristol-Myers Squibb Company. BMS-232632: atazanavir briefing document May 2003. Available from http://www.fda. gov/ohrms/dockets/ac/03/briefing/ 3950Bl_01_bristolmyerssquib b-atazanavir.pdf. Accessed August 5, 2005.
5. Taburet AM, Piketty C, Chazallon C, et al. Interactions between atazanavir-ritonavir and tenofovir in heavily pretreated human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2004;48:2091-6.
6. Shelton MJ, Ford SL, Wire MB, et al. Coadministration of esomeprazole (ESO) with fosamprenavir (fAPV) has no impact on steady-stale plasma amprenavir (APV) pharmacokinetics (APV10031). Presented at the 6th international workshop on clinical pharmacology of HIV therapy, Quebec City, Quebec, Canada, April 28-30, 2005.